Search results
Dr. Johnson, age 64, has served as the President of Wellesley College since 2016. She is a physician-researcher specializing in cardiology who founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital from July 2002 to June 2016.
Johnson & Johnson subsidiary Janssen Vaccines, in partnership with Beth Israel Deaconess Medical Center (BIDMC), was responsible for developing the vaccine candidate, based on the same technology used to make its Ebola vaccine.
Mar 12, 2021 · The World Health Organization (WHO) today listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use in all countries and for COVAX roll-out. The decision comes on the back of the European Medicines Agency (EMA) authorization, which was announced yesterday. “Every new, safe and effective tool against ...
Dr Nikki Kuiper. The Fellowship offered her the chance to use her extensive knowledge of the MSK field and combine it with the opportunity to harness new technology to analyse “big data” (large, complex data sets) on patients with knee cartilage problems.
- Who Can Take The Vaccine?
- Can Immunocompromised Persons Take The Vaccine?
- Should Pregnant Women Be Vaccinated?
- Who Is The Vaccine Not Recommended for?
- What’s The Recommended Dosage?
- Is It Safe?
- How Efficacious Is The Vaccine?
- Does It Work Against New Variants of Sars-Cov-2 Virus?
- Interchangeability Between Vaccine Products and Platforms
- Co-Administration with Inactivated Influenza Vaccines
The Janssen vaccine can be offered to people who have had COVID-19 in the past. But individuals may wish to choose to delay vaccination for 3 months following the infection.
Persons with immunocompromising conditions are at higher risk of severe COVID-19 and should be vaccinated. The WHO’s Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons can be viewed here. WHO recommends a second dose for all people with immunocompromising cond...
The Janssen vaccine is a nonreplicating vaccine. No safety issues have been identified following vaccination of more than 1,600 pregnant women using this vaccine platform for vaccines against other pathogens, such as the Ebola virus. Animal developmental and reproductive toxicity studies show no harm to the development of the foetus. WHO has identi...
Individuals with a history of anaphylaxis to any component of the vaccine should not take it. People who have had Thrombosis with thrombocytopenia (TTS) following the first dose of this vaccine should not receive a second dose of the same vaccine. Anyone with a body temperature over 38.5ºC should postpone vaccination until they no longer have a fev...
A single dose regimen, in keeping with the EUL recommendations for this vaccine, remains an acceptable option for countries, especially when faced with supply constraints and difficulties to reach remote populations. However, given the evidence demonstrating improved protection with a second dose, WHO recommends that all efforts should be taken to ...
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above. This vaccine has also undergone review by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) and found to be safe for use. A rare serious adverse event is the “thrombosis wit...
Studies show that a second dose 2 months after the initial dose substantially increases efficacy, especially against symptomatic infections, including when caused by SARS-CoV-2 variants of concern. In the US, the vaccine efficacy of 2 doses, 2 months apart, was 94%. In comparison, the single dose vaccine efficacy in the USA was 72%. Furthermore, in...
SAGE has reviewed all available data on the performance of the vaccine in the settings of the variants of concern. In clinical trials this vaccine has been tested against a variety of SARS-CoV-2 virus variants, including B1.351 (first identified in South Africa) and P.2 (first identified in Brazil), and found to be efficacious. There are no data ye...
Evolving evidence suggests that heterologous COVID-19 vaccine schedules (using WHO EUL vaccine products from different platforms) may be more immunogenic and effective than homologous schedules, depending on the specific platforms and order of the products used. In particular, data shows that individuals who have received one dose of the Janssen va...
COVID-19 vaccines may be given concomitantly, or any time before or after, other adult vaccines including inactivated influenza vaccines. Different arms for injection should be used when both vaccines are delivered during the same visit. Continued pharmacovigilance monitoring is recommended.
Jan 29, 2021 · Covid vaccine: Single-dose Johnson & Johnson jab is 66% effective. PA Wire. Dr Claire Cole from Manchester University NHS Foundation Trust volunteered in the Janssen jab's Phase 3 trial. A...
Sep 26, 2024 · Meet our. leadership team. At Johnson & Johnson Innovative Medicine, we apply rigorous science and compassion to confidently address the most complex diseases of our time. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Through continued listening and ...
